HOUSTON, Jan. 8, 2024 /PRNewswire/ -- Rice University today announced the addition of Robert Ruffolo Jr. to its external advisory board for the Rice Biotech Launch Pad, a Houston-based accelerator focused on expediting the translation of the university's health and medical technology discoveries into cures. .

休斯顿，2024年1月8日/PRNewswire/--莱斯大学今天宣布，其莱斯生物技术发射台（Rice Biotech Launch Pad）外部顾问委员会将增加罗伯特·鲁福洛（Robert Ruffolo Jr.），这是一家总部位于休斯顿的加速器，旨在加速将该大学的健康和医疗技术发现转化为治疗方法。。

Continue Reading

继续阅读

Dr. Robert Ruffolo

罗伯特·鲁弗洛博士

Ruffolo's vision and commitment to innovation will be fundamental in advancing the Launch Pad's mission to continuously identify and produce breakthrough therapies for patients, the accelerator's leadership said. During his 50-year career in pharmaceuticals, Ruffolo has been an executive leader at the highest levels in global drug research and development, contributing to the successful launch of numerous drugs..

加速器领导层表示，Ruffolo对创新的愿景和承诺将是推进发射台不断为患者识别和生产突破性疗法的使命的基础。在他50年的制药职业生涯中，Ruffolo一直是全球药物研究和开发领域最高级别的执行领导者，为众多药物的成功推出做出了贡献。。

'Kicking off 2024 with the significant announcement of the addition of Dr. Ruffolo to the external advisory board is setting us up to have another successful year,' said Paul Wotton, the Launch Pad's executive director and chairman. 'We introduced the Launch Pad in September of last year and in the past few months we have made substantial progress in terms of fundraising, research and development.

发射台执行董事兼主席保罗·沃顿（PaulWotton）说，2024年，随着鲁弗洛博士加入外部顾问委员会的重大宣布，这一年的开始，我们将迎来又一个成功的一年我们于去年9月推出了发射台，在过去几个月里，我们在筹资、研究和开发方面取得了实质性进展。

As a member of our external advisory board, Dr. Ruffolo will shape our plans to further expand how we translate our platform technologies into treatments in various therapeutic areas.'.

作为我们外部顾问委员会的成员，Ruffolo博士将制定我们的计划，进一步扩大我们如何将平台技术转化为各个治疗领域的治疗。”。

'Dr. Ruffolo brings immense value to the Rice Biotech Launch Pad as an adviser to drive drug development,' said Omid Veiseh, associate professor of bioengineering at Rice and faculty director of the Launch Pad. 'His networks and relationships built within this industry over his remarkable career will be crucial in guiding these innovative startups.

'博士。Rice生物工程副教授兼Launch Pad系主任Omid Veiseh说，作为推动药物开发的顾问，Ruffolo为Rice Biotech Launch Pad带来了巨大的价值在他卓越的职业生涯中，他在这个行业建立的网络和关系对于指导这些创新创业公司至关重要。

Together with the rest of our extraordinary external advisory board, Dr. Ruffolo will provide us with the necessary strategic guidance to continuously make breakthroughs in the drug discovery field.''The Rice Biotech Launch Pad is one of the most forward-looking and technologically innovative teams in the drug development space right now,' Ruffolo said.

Ruffolo博士将与我们非凡的外部顾问委员会的其他成员一起，为我们提供必要的战略指导，以不断在药物发现领域取得突破。”Ruffolo说，水稻生物技术发射台是目前药物开发领域最具前瞻性和技术创新的团队之一。

'Through our collaboration with the Texas Medical Center, we envision a future in which our innovations can rapidly reach our patients and create a profound impact in their lives. I am honored to be a part of the outstanding external advisory board and look forward to being an advisor to these programs.'Ruffolo is currently serving as chairman of Aragen Biosciences and managing director of Ruffolo Consulting, LLC, a consulting company for the pharmaceutical and biotechnology industries.

“通过与德克萨斯州医疗中心的合作，我们设想了一个未来，在这个未来，我们的创新可以迅速惠及患者，并对他们的生活产生深远影响。我很荣幸成为杰出外部顾问委员会的一员，并期待成为这些项目的顾问。”Ruffolo目前担任Aragen Biosciences董事长兼Ruffolo Consulting，LLC董事总经理，Ruffolo Consulting，LLC是一家制药和生物技术行业的咨询公司。

He is the former president of research and development of Wyeth Pharmaceuticals, now Pfizer. At Wyeth, he also served as chief scientific officer and corporate senior vice president. Prior to Wyeth, Ruffolo held executive positions at companies such as Eli Lilly & Co. and SmithKline Beecham Pharmaceuticals.

他是惠氏制药（Wyeth Pharmaceuticals）前研发总裁，现为辉瑞（Pfizer）。在惠氏，他还担任首席科学官和公司高级副总裁。在惠氏之前，鲁弗洛曾在礼来公司（Eli Lilly＆Co.）和史克比查姆制药（SmithKline Beecham Pharmaceuticals）等公司担任高管职位。

Throughout his career, Ruffolo and his teams have successfully brought to market 37 new drugs. He also has published over 500 papers and edited 15 books. He received a Bachelor of Science in pharmacy and his Ph.D. in pharmacology, both from The Ohio State University.Ruffolo is the 13th membe.

在他的职业生涯中，鲁弗洛和他的团队成功地将37种新药推向市场。他还发表了500多篇论文，编辑了15本书。他拥有俄亥俄州立大学药学学士学位和药理学博士学位。Ruffolo是第13个成员。